MAI Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.8M Buy
614,061
+193,369
+46% +$5.06M 0.06% 266
2026
Q1
$11.8M Buy
420,692
+14,038
+3% +$374K 0.07% 253
2025
Q4
$10.1M Buy
406,654
+13,605
+3% +$343K 0.06% 270
2025
Q3
$10M Buy
393,049
+28,163
+8% +$695K 0.06% 256
2025
Q2
$8.84M Sell
364,886
-1,009,573
-73% -$23.5M 0.06% 256
2025
Q1
$34.8M Sell
1,374,459
-5,149
-0.4% -$135K 0.26% 87
2024
Q4
$36.6M Buy
1,379,608
+681,950
+98% +$18.5M 0.27% 87
2024
Q3
$20.2M Buy
697,658
+11,381
+2% +$332K 0.19% 97
2024
Q2
$19.2M Sell
686,277
-25,613
-4% -$705K 0.19% 97
2024
Q1
$19.8M Buy
711,890
+74,983
+12% +$2.08M 0.2% 101
2023
Q4
$18.3M Buy
636,907
+337,538
+113% +$10.2M 0.24% 85
2023
Q3
$9.93M Sell
299,369
-11,224
-4% -$397K 0.15% 132
2023
Q2
$11.4M Sell
310,593
-13,054
-4% -$508K 0.17% 119
2023
Q1
$13.2M Sell
323,647
-12,497
-4% -$540K 0.21% 108
2022
Q4
$17.2M Buy
336,144
+15,620
+5% +$749K 0.29% 77
2022
Q3
$14M Buy
320,524
+53,338
+20% +$2.59M 0.26% 89
2022
Q2
$14M Buy
267,186
+19,245
+8% +$981K 0.27% 87
2022
Q1
$12.8M Buy
247,941
+497
+0.2% +$25.8K 0.22% 100
2021
Q4
$14.6M Buy
247,444
+42,080
+20% +$2.08M 0.24% 95
2021
Q3
$8.83M Sell
205,364
-196
-0.1% -$8.68K 0.17% 113
2021
Q2
$8.05M Buy
205,560
+3,358
+2% +$131K 0.16% 121
2021
Q1
$7.33M Buy
202,202
+17,440
+9% +$619K 0.16% 118
2020
Q4
$6.8M Buy
184,762
+15,946
+9% +$585K 0.17% 115
2020
Q3
$5.88M Sell
168,816
-1,724
-1% -$60.4K 0.17% 111
2020
Q2
$5.29M Buy
170,540
+5,652
+3% +$192K 0.17% 110
2020
Q1
$5.11M Buy
164,888
+3,084
+2% +$105K 0.21% 98
2019
Q4
$6.01M Buy
161,804
+63,999
+65% +$2.28M 0.19% 102
2019
Q3
$3.33M Sell
97,805
-13,506
-12% -$491K 0.15% 128
2019
Q2
$4.58M Buy
111,311
+12,586
+13% +$500K 0.21% 111
2019
Q1
$3.98M Sell
98,725
-6,150
-6% -$246K 0.2% 116
2018
Q4
$4.34M Buy
104,875
+3,885
+4% +$161K 0.25% 99
2018
Q3
$4.22M Sell
100,990
-10,639
-10% -$410K 0.22% 111
2018
Q2
$3.84M Buy
111,629
+2,369
+2% +$81K 0.21% 119
2018
Q1
$3.68M Buy
109,260
+6,335
+6% +$218K 0.21% 115
2017
Q4
$3.54M Sell
102,925
-19,155
-16% -$653K 0.2% 117
2017
Q3
$4.13M Sell
122,080
-59
-0% -$1.9K 0.25% 103
2017
Q2
$3.89M Sell
122,139
-6,417
-5% -$202K 0.25% 104
2017
Q1
$4.17M Sell
128,556
-17,313
-12% -$546K 0.28% 98
2016
Q4
$4.5M Buy
145,869
+3,092
+2% +$94.4K 0.33% 91
2016
Q3
$4.59M Buy
142,777
+7,011
+5% +$234K 0.35% 83
2016
Q2
$4.54M Sell
135,766
-52,208
-28% -$1.67M 0.35% 80
2016
Q1
$5.29M Buy
187,974
+9,156
+5% +$262K 0.4% 73
2015
Q4
$5.48M Buy
178,818
+5,817
+3% +$183K 0.42% 72
2015
Q3
$5.16M Sell
173,001
-6,243
-3% -$200K 0.39% 80
2015
Q2
$5.7M Buy
179,244
+21,133
+13% +$689K 0.38% 82
2015
Q1
$5.22M Sell
158,111
-3,636
-2% -$116K 0.35% 86
2014
Q4
$4.78M Sell
161,747
-322
-0.2% -$9.23K 0.34% 81
2014
Q3
$4.55M Buy
162,069
+36,688
+29% +$1.03M 0.44% 65
2014
Q2
$3.53M Buy
125,381
+42,889
+52% +$1.22M 0.34% 77
2014
Q1
$2.51M Buy
82,492
+9,568
+13% +$285K 0.25% 93
2013
Q4
$2.12M Sell
72,924
-1,800
-2% -$52.4K 0.22% 93
2013
Q3
$2.04M Buy
74,724
+10,806
+17% +$294K 0.26% 77
2013
Q2
$1.7M Buy
+63,918
New +$1.77M 0.22% 83

Other funds holding PFE

MAI Capital Management's PFE Position: Q2 2026 in Review

MAI Capital Management increased its Pfizer (PFE) stake by 46% in Q2 2026, buying an estimated $5.06M and bringing the position to 614,061 shares worth $14.8M. The position accounts for 0.06% of the portfolio, ranked #266.

MAI Capital Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $36.6M in Q4 2024. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • MAI Capital Management held 614,061 shares of Pfizer worth $14.8M as of Q2 2026.
  • MAI Capital Management bought 193,369 Pfizer shares in Q2 2026, an estimated $5.06M.
  • Pfizer made up 0.06% of MAI Capital Management's portfolio in Q2 2026, its #266 holding.
  • MAI Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • MAI Capital Management's Pfizer position peaked at $36.6M in Q4 2024.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.